Research & Regulatory News

Retatrutide TRIUMPH-2 and TRIUMPH-3: What They Added

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Eli Lilly reported TRIUMPH-2 and TRIUMPH-3 in July 2026. Both met their primary endpoints. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease, reported mean weight reduction up to 22.6% at 80 weeks. Together they extend the programme beyond uncomplicated obesity into its two most clinically significant comorbid populations.

Key facts

Reported
July 2026
TRIUMPH-2 population
Obesity with type 2 diabetes
TRIUMPH-3 population
Severe obesity with established CVD
TRIUMPH-3 result
Up to 22.6% mean reduction at 80 weeks
Primary endpoints
Met in both trials
Programme enrolment
More than 5,800 participants
Planned FDA filing
Q1 2027

Why these two trials matter more than the headline number

TRIUMPH-1 answered how much weight reduction is achievable in a relatively uncomplicated obesity population. That is the easier question. TRIUMPH-2 and TRIUMPH-3 ask whether the same compound performs in people who actually carry the conditions that make obesity dangerous. Type 2 diabetes in one case, established cardiovascular disease in the other. Regulators and payers weight these populations heavily, because they are where the clinical benefit has to be demonstrated.

TRIUMPH-3 and the cardiovascular population

In adults with severe obesity and established cardiovascular disease, mean reduction reached up to 22.6% at 80 weeks. The figure is lower than TRIUMPH-1's 28.3%, which is expected: this is an older, sicker population with more concomitant medication and different tolerability constraints. That it met its primary endpoint in this group is the substantive finding.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

TRIUMPH-2 and glycaemic control

The type 2 diabetes study reported improvements in both body weight and A1C. Weight reduction in diabetic populations is typically attenuated compared with non-diabetic ones across the entire incretin class, so comparisons should be made within population rather than against the TRIUMPH-1 headline.

What is still outstanding

Seven further Phase 3 readouts were expected across 2026, including studies of maintenance dosing strategies. That is, what happens when the dose is reduced or stopped after the initial reduction phase. Weight regain after discontinuation is the open question across the whole incretin class, and maintenance data are what the field is actually waiting on.

Regulatory position

Positive pivotal data do not confer authorisation. Retatrutide remains investigational in every jurisdiction, including the UK. Lilly has indicated an intended Biologics License Application to the FDA in the first quarter of 2027; MHRA and EMA timelines have not been stated publicly.

Frequently asked questions

Why is the TRIUMPH-3 number lower than TRIUMPH-1?

Different populations. TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, in whom attenuated response is the expected pattern across the class.

Has retatrutide been submitted to the MHRA?

No public filing has been announced with the MHRA. The stated plan is an FDA submission in Q1 2027.

What are the maintenance trials looking at?

Whether reduction is sustained when dosing is lowered or stopped. This is the main unresolved question for incretins generally, not only for retatrutide.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.